Dyadic International (NASDAQ:DYAI) Stock Price Passes Above 50-Day Moving Average – Time to Sell?

Shares of Dyadic International Inc. (NASDAQ:DYAI) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.81 and traded as high as $1.34. Dyadic International shares last traded at $1.21, with a volume of 770,602 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dyadic International currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Dyadic International Price Performance

The company has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $0.83. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The company has a market capitalization of $44.09 million, a price-to-earnings ratio of -5.26 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The business had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.90 million. As a group, research analysts anticipate that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On Dyadic International

Several large investors have recently added to or reduced their stakes in DYAI. Bank of America Corp DE grew its holdings in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the period. Geode Capital Management LLC raised its stake in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Marathon Capital Management raised its stake in Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 50,000 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new position in Dyadic International during the third quarter worth approximately $190,000. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.